Children ages 3-17 receiving antipsychotic therapy

IRB/UVA Tracking #
21512
Principal Investigator
Vishal Madaan
Contact
Kristina Muniz
Contact Phone
434.243.3678
Official Trial Title
Long-term antipsychotic pediatric safety trial (LAPS)
Study Description

The department of psychiatry and neurobehavioral sciences, division child and family psychiatry is seeking children ages 3-17 receiving antipsychotic therapy for a research study. The purpose of the study is to learn about the long-term changes to weight in children who are taking risperidone (Risperdal®) or aripiprazole (Abilify®).

You and your child may be eligible for this study if your child is 3-17 years old and prescribed risperidone or aripiprazole. Qualified indications include: irritability associated with autistic disorder/autism spectrum disorder; treatment of Tourette’s disorder or persistent tic disorder; bipolar mania, treatment of manic and mixed episodes associated with Bipolar I disorder and Bipolar spectrum disorders including disruptive mood dysregulation disorder; or Schizophrenia spectrum disorders including schizoaffective disorder, psychosis not otherwise specified, and delusional disorder.

Study involves blood draws, physical exams and assessments of development and quality of life. There will be approximately 5 visits to the study center over 24 months and remote monthly contact in between visits. During the study, your child will continue to receive care from their personal medical provider (PMP). No drugs will be given as a part of this study.

All study-related exams and lab work are provided at no cost to you or your insurance.

Compensation

$50.00 per completed in-clinic study visit for reimbursement for time and travel related expenses